Fegan C - Search Results

1

Understanding cancer cell survival is key to patient survival.

Fegan C, Pepper C. Fegan C, et al. Lancet Oncol. 2015 Feb;16(2):122-4. doi: 10.1016/S1470-2045(15)70003-3. Lancet Oncol. 2015. PMID: 25638674 No abstract available.

2

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.

Lewis T, Corcoran DB, Thurston DE, Giles PJ, Ashelford K, Walsby EJ, Fegan CD, Pepper AGS, Miraz Rahman K, Pepper C. Lewis T, et al. Among authors: fegan cd. Haematologica. 2021 Apr 1;106(4):958-967. doi: 10.3324/haematol.2019.238584. Haematologica. 2021. PMID: 32381576 Free PMC article.

3

Telomere length predicts for outcome to FCR chemotherapy in CLL.

Norris K, Hillmen P, Rawstron A, Hills R, Baird DM, Fegan CD, Pepper C. Norris K, et al. Among authors: fegan cd. Leukemia. 2019 Aug;33(8):1953-1963. doi: 10.1038/s41375-019-0389-9. Epub 2019 Jan 30. Leukemia. 2019. PMID: 30700843 Free PMC article.

4

NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.

Pepper C, Hewamana S, Brennan P, Fegan C. Pepper C, et al. Among authors: fegan c. Future Oncol. 2009 Sep;5(7):1027-37. doi: 10.2217/fon.09.72. Future Oncol. 2009. PMID: 19792971 Review.

5

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis.

Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM. Lin TT, et al. Among authors: fegan c. Blood. 2010 Sep 16;116(11):1899-907. doi: 10.1182/blood-2010-02-272104. Epub 2010 Jun 10. Blood. 2010. PMID: 20538793 Free article.

6

A novel tumor antigen derived from enhanced degradation of bax protein in human cancers.

Nunes CT, Miners KL, Dolton G, Pepper C, Fegan C, Mason MD, Man S. Nunes CT, et al. Among authors: fegan c. Cancer Res. 2011 Aug 15;71(16):5435-44. doi: 10.1158/0008-5472.CAN-11-0393. Epub 2011 Jun 22. Cancer Res. 2011. PMID: 21697278 Free article.

7

Defining the prognosis of early stage chronic lymphocytic leukaemia patients.

Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C. Pepper C, et al. Among authors: fegan c. Br J Haematol. 2012 Feb;156(4):499-507. doi: 10.1111/j.1365-2141.2011.08974.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171799 Free article.

8

Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Nunes C, et al. Among authors: fegan c. Clin Cancer Res. 2012 Feb 1;18(3):678-87. doi: 10.1158/1078-0432.CCR-11-2630. Epub 2011 Dec 21. Clin Cancer Res. 2012. PMID: 22190592

9

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. Walsby E, et al. Among authors: fegan c. Oncotarget. 2012 May;3(5):525-34. doi: 10.18632/oncotarget.491. Oncotarget. 2012. PMID: 22619113 Free PMC article.

10

Apoptosis deregulation in CLL.

Fegan C, Pepper C. Fegan C, et al. Adv Exp Med Biol. 2013;792:151-71. doi: 10.1007/978-1-4614-8051-8_7. Adv Exp Med Biol. 2013. PMID: 24014296 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters